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Background: Zinc oxide nanoparticles (ZnO NPs) are used in modern cancer therapy based
on their speciﬁc target, efﬁcacy, low toxicity and biocompatibility. The photocatalytic
performance of Zinc oxide (ZnO) nanocomposites with hyaluronic acid (HA) was used to
study anticancer properties against various human cancer cell lines.
Methods: Zinc oxide (ZnO) nanocomposites functionalized by hyaluronic acid (HA) were
prepared by a co-precipitation method (HA-ZnONcs). The submicron-ﬂower-shaped nano-
composites were further functionalized with ginsenoside Rh2 by a cleavable ester bond via
carbodiimide chemistry to form Rh2HAZnO. The physicochemical behaviors of the synthe-
sized ZnO nanocomposites were characterized by various analytical and spectroscopic
techniques. We carried out 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyl tetrazolium bromide
(MTT) assay to evaluate the toxicity of Rh2HAZnO in various human cancer cells (A549,
MCF-7, and HT29). Furthermore, to conﬁrm the apoptotic effects of Rh2HAZnO and to
determine the role of the Caspase-9/p38 MAPK pathways by various molecular techniques
such as RT-PCR and Western blotting. Furthermore, Rh2HAZnO induced morphological
changes of these cell lines, mainly intracellular reactive oxygen species (ROS) were
observed by ROS staining and nucleus by Hoechst staining.
Results: We conﬁrmed that Rh2HAZnO exhibits the anti-cancer effects on A549 lung cancer,
HT29 colon cancer, andMCF7 breast cancer cells. Moreover, intracellular reactive oxygen species
(ROS) were observed in three cancer cell lines. Rh2HAZnO induced apoptotic process through
p53-mediated pathway by upregulating p53 and BAX and downregulating BCL2. Speciﬁcally,
Rh2HAZnO induced activation of cleaved PARP (Asp214) in A549 lung cancer cells and upregu-
lated Caspase-9/phosphorylation of p38 MAPK in other cell lines (HT29 and MCF-7).
Furthermore, Rh2HAZnO induced morphological changes in the nucleus of these cell lines.
Conclusion: These results suggest that the potential anticancer activity of novel
Rh2HAZnO nanoparticles might be linked to induction of apoptosis through the generation
of ROS by activation of the Caspase-9/p38 MAPK pathway.
Keywords: zinc oxide nanocomposites, ginsenoside Rh2, Dendropanax morbifera Léveille,
cytotoxicity, anticancer activity, drug delivery
Introduction
The Global Cancer Observatory estimates of the incidence of mortality and pre-
valence from major types of cancers such as lung, breast, and liver for 184 countries
of the world revealed that there were 14.1 million new cancer cases, 8.2 million
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cancer deaths, and 32.6 million people living with cancer.1
By 2030, it is projected that there will be 26 million new
cancer cases and 17 million cancer deaths per year.2
Besides, during the last decade, novel synthetic che-
motherapeutic agents currently used for the treatment of
cancer have not succeeded in fulﬁlling expectations
despite the considerable cost of their development.
Consequently, there is constant demand to develop new,
target-speciﬁc, and affordable anticancer drugs.3
Nanomedicine is the ﬁeld of biomedical application of
nanotechnology in which contrived nanoparticles (NPs)
are used to treat diseases.4 Nanomedicine, with its inno-
vative imaging and therapeutic competencies, has the pro-
spective for early detection of cancer and cancer
treatment.5 Nanomaterials can also be functionalized with
biomolecules, to ensure target speciﬁcity, increasing the
biocompatibility and characteristic of multifunctional.6
ZnO nanoparticles are nano-sized (less than 100 nm) par-
ticles and have a wide range of biomedical application
such as cosmetics and facial products.7 ZnO nanoparticles
are now being extensively researched for their anticancer
properties. The effect of ZnO on the cytotoxic and apop-
totic mechanism by releasing ZnO materials which induce
cell death and it also suggest that requirement for ZnO
dissolution for effective cytotoxicity.8 The main bioactive
components of ginseng are triterpenoids collectively clas-
siﬁed as ginsenosides. Among these ginsenosides, the
metabolites of protopanaxadiol (PPD)-type ginsenosides
are predominantly transformed into compound K (CK)
and ginsenoside Rh2.9 These minor ginsenosides often
exhibit superior pharmacological effects compared to
their precursors.10 However, their clinical application is
signiﬁcantly limited due to their hydrophobic saponin
backbone, poor bioavailability and absorption, and non-
targeted cytotoxicity to normal cells.11 So biomolecular
conjugations of ginsenosides with ZnO and drug delivery
techniques play a signiﬁcant role in solving these proble-
matic issues.12
Zinc is an obligatory trace element for humans and
plays an important role in regulating cellular metabolism.
The Food and Drug Administration (FDA) included ZnO
in the list of generally recognized as a safe (GRAS)
material based on their biodegradable, less toxic and easily
absorbed by the body.13 Previous research stated that
photocatalytic or photoluminescent effect of ZnONPs
under light irradiation can produce reactive oxygen species
(ROS) such as hydroxyl radicals and hydrogen peroxide
which enable cell death and efﬁcient decomposition of
organic compounds.14 The objective of this study is to
develop zinc oxide nanocarriers with ginsenoside by
green synthesis. Zinc oxide nanoparticles help improve
water dispersibility (poorly water-soluble ginsenosides),
stability, and therapeutic effect agents that may elevate
their capacities as effective anticancer agents. Zinc oxide
(ZnO) nanocomposites functionalized by hyaluronic acid
(HA) were prepared by a co-precipitation method
(HA-ZnONcs), and the physiochemical properties of
Rh2HAZnO were well characterized by spectroscopic ana-
lysis. In this study, we evaluated the potential effect of
Rh2HAZnO nanoparticles to induce apoptotic-medicated
cell death by damaging the nucleus and its materials in
various human cancer cell lines, such as lung cancer
(A549) cells, colon cancer (HT29) cells, and breast cancer
(MCF7) cells. Elucidation of the effect of Rh2HAZnO on
Caspase-9/p38 MAPK mediated pathway through upregu-
lation of the gene and proteins by anticancer activity.
Experimental Section
Materials And Methods
The leaves of six-year-old Dendropanax morbifera
Léveille and ginsenoside Rh2 (≥90%) were acquired
from Ginseng Bank, Kyung Hee University (Yongin,
Republic of Korea). High-molecular-weight sodium hya-
luronate (HA, MW = 1,280 kDa) was supplied by Xinjiang
Fufeng Biotechnologies Co., Ltd. (Xinjiang, China). Zinc
nitrate hexahydrate (reagent grade, ≥98%), N-(3-dimethy-
laminopropyl)-N’-ethylcarbodiimide hydrochloride (EDC,
reagent grade, ≥98%), 4-(dimethylamino) pyridine
(DMAP, ≥99%), hydrochloric acid (HCl, ACS reagent,
37%), and anhydrous N,N-dimethylformamide (DMF,
≥99%) were purchased from Sigma-Aldrich Chemicals
(St. Louis, MO, USA). Phosphate buffer (20× PBS) was
purchased from Biosesang (Seongnam, Republic of
Korea). Trichloroacetic acid (TCA, ≥ 99%), potassium
persulfate (≥98%), potassium ferricyanide (≥98%), sodium
chloride (NaCl, ≥99.50%), and sodium hydroxide (NaOH,
≥98%) were purchased from Daejung Chemicals and
Metals Co., Ltd. (Siheung, Republic of Korea). Glycerol
was purchased from Junsei Chemical Co., Ltd (Tokyo,
Japan). Iron (III) chloride hexahydrate (97%), methyl alco-
hol (MeOH, 95%), and ethyl alcohol (EtOH, 95%) were
procured from Samchun Pure Chemical Co. Ltd.
(Pyeongtaek, Republic of Korea). Other chemicals and
reagents were purchased from commercial suppliers.
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Synthesis And Characterization Of
Rh2HAZnO
Synthesis of hyaluronic acid-functionalized ZnO
(Rh2HAZnO) nanoparticle was prepared as per our pre-
vious study.12 The hyaluronic acid-functionalized ZnO
was prepared by a NaOH-assisted co-precipitation method
using zinc nitrate hexahydrate as a salt precursor and poly-
mers as steric stabilizing agents. Aqueous leaf extract of D.
morbifera was incorporated in the synthesis to enhance
water stability and was synthesized as in a previous study,
and the physiochemical properties were analyzed and
reported.15 For characterization of nanoparticles, we have
used scanning electron microscopy (SEM), and elemental
mapping was performed. The previous study includes spec-
trophotometry (UV-Vis), ﬁeld emission-transmission elec-
tron microscopy (FE-TEM), X-ray diffraction (XRD), zeta
potential and hydrodynamic particle size of nanocompo-
sites, and Fourier-transform infrared (FTIR) spectroscopy.
Drug loading content of Rh2HAZnO was quantiﬁed by
liquid chromatography-mass spectrometry (LC-MS),
approximately 0.32 µg of ginsenoside Rh2 per 1 mg of
Rh2-HA-ZnONcs was detected.
Photoluminescence Spectra
The photoluminescence (PL) spectra were measured at
room temperature using the 325-nm line of a HeCd laser
as the excitation source. Emitted light was collected by a
lens and analyzed using a grating monochromator and a
GaAs photomultiplier tube. Standard lock-in detection tech-
niques were used to maximize the signal-to-noise ratio. The
laser power for the PL excitation was about 5.66 W/cm2.
Total Internal Reﬂection Scattering (TIRS)
The schematic representation and physical layout of the
apparatus were modiﬁed from previously published
protocols.16 The TIRS microscopy was carried out with
upright Olympus BX51 microscope (Olympus Optical Co.,
Ltd., Tokyo, Japan) equipped with a 100× oil iris objective
lens (NA = 0.6–1.3, UPLANFLN, Olympus Optical Co.,
Ltd., Tokyo, Japan). The smallest NA value (i.e., 0.6) was
used for all the experiments. TIR illumination was con-
ducted with a 30-mW, 637-nm laser (MGL-III-637-200
mW, Changchun New Industries Optoelectronics Tech.
Co., Ltd., China) for illumination of the gold nanoparti-
cles. A Uniblitz mechanical shutter (model LS3S2ZO-R3,
Vincent Associates, Rochester, NY, USA) and a driver
(model VMM-D1, Vincent Associates) were synchronized
to an electron-multiplying cooled charge-coupled device
(EMCCD) camera (512 × 512 pixel imaging array,
QuantEM 512SC, Tucson, AZ, USA). The exposure time
was 100 ms. Wavelength selection was accomplished with
a central wavelength of 620/14 nm on an instrument pur-
chased from Semrock (Rochester, NY, USA).
Cell Lines
Human lung carcinoma (A549), human colon carcinoma
(HT29), breast cancer (MCF7) cell lines and normal
human keratinocytes (HaCaTs) were purchased from the
American Type Culture Collection (ATCC) (Manassas,
VA, USA). All cell lines were grown in RPMI 1640
medium supplemented with 10% fetal bovine serum and
1% penicillin and streptomycin, at 37 °C in 5% CO2.
Cell Viability Assay
The cell cytotoxicity of Rh2HAZnO toward the various
human cancer cell lines (A549, HT29, and MCF-7) was
evaluated using an MTT assay. MTT stock solution (10×)
(5mg/mL) was dissolved in phosphate-buffered saline (PBS)
(pH 7.4), ﬁlter sterilized and stored at −20 °C. We used
2 × 104 cells per well (96-well plates) containing 100 μL of
the complete culture medium. After 24 hrs, the test samples
of different concentrations were added onto 96-well plates.
The ﬁnal concentration of DMSO Hybri-Max in all assays
was less than 0.1%. Based on the preliminary test results, the
anti-proliferative activity of Rh2HAZnO was determined
with ﬁve to six concentrations ranging from 0 to 200 μg in
0.1%DMSO. The culture plates were incubated for 2 days in
a 37 °C supplied with a humidiﬁed atmosphere of 5% CO2.
The plates were then washed with 100 μL PBS, and 0.05% of
100 μL MTT reagent was added to each well and then
incubated for 4 hrs as stated previously. MTT solution was
removed, and 200 μL DMSO was added to each well.
Finally, the plate was shaken in a microplate shaker for 10
mins in dark condition to dissolve the purple formazan crys-
tals. The DMSO solution is used as a negative control. The
optical density values were recorded using a VersaMax
microplate reader (Molecular Devices, Sunnyvale, CA,
USA) at a 560 nm and 670 nm, respectively. Blank values
were subtracted from experimental values.
Reactive Oxygen Species (ROS)
Generation
Free radical scavengers were analyzed by DPPH
method, and intracellular ROS was measured by
Dovepress Kim et al
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2′,7′-dichlorodihydro-ﬂuorescein diacetate (DCFH-DA),
as previously described.8 In brief, all three cell lines
(2×105/well) were treated with different concentrations of
Rh2HAZnO (10 and 20 μg/mL) for 24 hrs. Then, 100 μL
of DCFH-DA was added at 25 μM and incubated for
30 mins. Next, media were discarded and cells were
washed twice with 1× PBS. The supernatant was kept in
a 96-well plate in the dark, and the ﬂuorescence intensity
was determined with a spectroﬂuorometer with excitation
at 485 nm and emission at 520 nm.
Apoptosis Detection
Hoechst-33258 staining was performed to capture the
apoptotic induction of Rh2HAZnO in A549, HT29, and
MCF7 cells. Cells were seeded into a 6-well plate at a
density of 1 × 105 cells/well in 2 mL medium and incu-
bated at 37 °C with 5% CO2 overnight. The cells were
then treated for 48 hrs and then stained with Hoechst-
33258 solution at 2 μg/mL for 20 mins following our
previous protocol. Scale bars were added using ImageJ
software.
Quantitative Real-Time Reverse
Transcription-PCR Analysis
Treated and non-treated cultures of A549, HT29, and
MCF7 cell monolayers grown in 25-cm2 cell culture ﬂasks
(Corning Costar, NY, USA) were treated with different
concentrations of Rh2HAZnO (µg/mL). After 24 hrs of
treatments, the total RNA was extracted from non-treated
and treated cultures using the RNeasy mini kit (Qiagen,
Hilden, Germany). For Real-time quantitative PCR (qRT-
PCR), 500 ng of total RNA was reverse transcribed using
oligo (dT) 15 primer (0.2 mM), and AMV Reverse
Transcriptase (10 units/μL) and cDNA were synthesized
using Superscript First-Strand Synthesis Kit (Invitrogen,
Carlsbad, CA) according to the manufacturer’s instruc-
tions. qRT-PCR was performed in 96-well plate using
100 ng of cDNA in a 20 μL reaction volume using
SYBR® Green Sensimix Plus Master Mix (Quantace,
Watford, England). The melting point analysis of PCR
products was carried out, which resulted in a single peak,
indicating the presence of a single PCR product ampliﬁca-
tion. The thermal cycler conditions recommended by the
manufacturer were used as follows: 10 mins at 95 °C,
followed 40 cycles of 95 °C for 10 s, 58 °C for 10 s,
and 72 °C for 20 s. The ﬂuorescent product was detected at
the last step of each cycle and measured in the real-time
reverse transcriptase PCR thermocycler, and its genomic
increase of the ﬂuorescence corresponding to the exponen-
tial increase of the product was used to determine the
threshold cycle (Ct) in each reaction using the formula
2−ΔΔCt (Livak & Schimittgen, 2001). The housekeeping
gene encoding β-actin was used as a standard for all
samples. All the real-time experiments were performed in
triplicates, and statistical analysis was determined using
Student’s t-test.
Western Blotting
Three human cancer cell lines (2×105/well) were treated
with different concentrations (µg/mL) of Rh2HAZnO 0.1
mL DMSO for about 24 hrs. The cells were then har-
vested and washed twice with cold PBS. The cell pellets
were lysed using RIPA lysis buffer (Sigma-Aldrich). The
controls received 0.1% DMSO. The lysates were then
centrifuged at 12,000 rpm for 20 mins at 4 °C. The
protein content of the supernatant was determined using
a Bradford Protein Assay kit, and BSA was used as the
standard. The total proteins (15 μg) were mixed with an
equal volume of 5× sample buffer containing 40 mM of
DL-dithiothreitol, boiled for 10 mins, and then loaded
onto 10% sodium dodecyl sulfate-polyacrylamide gels
using a Mini-Protean 3 electrophoresis cell (Bio-Rad,
Hercules, CA, USA). After electrophoresis at 150V for
1.5 hrs, the proteins from the gels were transferred onto a
polyvinyl diﬂuoride membrane (Pall Corporation,
Pensacola, FL, USA) using an electroblotting apparatus.
The membrane was then blocked with 5% skim milk (BD
Difco, Franklin Lakes, NJ, USA) in PBS containing 0.1%
(v/v) Tween-20 (PBS-T) at room temperature for 1 hr and
further incubated overnight at 4 °C with a speciﬁc mono-
clonal or polyclonal antibody stated previously, each of
them were used at a dilution of 1:1000 dilution. After
washing with 0.1% PBS-T three times at 10-min inter-
vals, the membranes were further incubated with a goat
anti-rabbit IgG H&L (HRP) secondary antibody at a
1:5000 dilution for 2hrs RT. Finally, after washing with
0.1% PBS-T three times with a 10-min interval between
washes, the blots were developed with an ECL chemilu-
minescence reagent and immediately exposed to a CP-PU
X-ray ﬁlm (AGFA, Mortsel, Belgium). The differences in
protein expression were quantiﬁed using a Molecular
Imager Gel Doc XR system (Bio-Rad, Hercules, CA,
USA) and normalized to actin expression on the same
membrane.
Kim et al Dovepress
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Statistical Analysis
Results are expressed as mean ± SEM. The statistical
signiﬁcance of differences between values was evaluated
by one-way ANOVA. The statistical analysis was per-
formed using Graph Pad 6.04 software (La Jolla, CA,
USA). All experiments were performed at least in tripli-
cate (n≤3) unless stated otherwise. Experimental data are
reported as the means ± standard error (SEM). Statistical
signiﬁcances between control and sample groups were
evaluated by Student’s t-test with two-tailed distribution
and two-sample equal variances. The extent of statistical
signiﬁcance was assigned by an increasing number of
asterisks (*P<0.05, **P<0.01, and ***P<0.001).
Results And Discussion
Characterization Nanoparticles By SEM
The interactions of HA-ZnO with Rh2, PL spectroscopy
was performed for the conﬁrmation of the interaction.
Figure 1A shows PL spectra of Rh2, HA-ZnO, and
Rh2HAZnO, excited by a 325-nm laser line. The major
PL peak of Rh2 is observed at ~410 nm, and the PL
spectrum of Rh2 ranges widely from 350 to 650 nm. The
Figure 1 Characterization of nanoparticles.
Notes: (A) The photoluminescence (PL) spectra were measured at room temperature using the 325-nm line of a HeCd laser as the excitation source. Emitted light was
collected by a lens and analyzed using a grating monochromator and a GaAs photomultiplier tube scanning electron microscope (SEM) images. (B) SEM images of
Rh2HAZnO. (C) EDS spectrum of complete element distribution. (D–F) Element analytical maps of Zn, oxygen, and carbon.
Dovepress Kim et al
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PL spectrum of the HAZnO shows a new peak at 570 nm
with a stoke shift of 210 nm, compared to the absorption
band at 360 nm, as shown in Figure 1A (absorbance
spectrum of HA-Zn nanoparticles). The PL intensity at
570 nm of HAZnO with Rh2 (Rh2HAZnO) is increased
by about 2 times that of the HAZnO, while the PL inten-
sity at 410 nm was almost unchanged. This observation
means that HAZnO and Rh2 interacted with each other
(Figure 1A). The surface morphology was analyzed by
SEM and revealed that formation of Rh2HAZnO nanopar-
ticles (Figure 1B). Element mapping conﬁrmed the pre-
sence of Zn, oxygen, and carbon (Figure 1C–F).
To develop new anticancer therapies, the study of nano-
technology-based therapies for cancer has been increasing
over the years.4 Nanotechnology-based therapies circulate
in the bloodstream and are undetected by the immune
system, which decreases the side effects associated with
conventional anticancer treatments.17,18 The Rh2HAZnO
characterized by X-ray diffraction pattern, FE-TEM, DLS,
and FTIR spectra, several functional residues were impli-
cated, such as O-H, C=O group of esters, N-H of amide
groups, and C-C=C stretching. The PL spectra were mea-
sured at RT using the 325-nm line of a HeCd laser as the
excitation source. Emitted light was collected by a lens and
analyzed using a grating monochromator and a GaAs
photomultiplier tube. Standard lock-in detection techniques
were used to maximize the signal-to-noise ratio. The laser
power for PL excitation was about 5.66 W/cm2. Based on
HPLC result, the Rh2HAZnO contained the ginsenoside
Rh2 (Figure S1). As the PL value increases, the physical
properties such as crystallinity, charge content, and carrier-
forming ability increased while the transfer of ginsenoside
Rh2 bound to this structure may affect the anticancer
activity.19
Analysis Of Mitochondria And Nucleus
Staining Analysis
TIRS of Rh2HAZnO, which was used to treat lung cancer
A549 cells, is presented in Figure 2A. In the dark ﬁeld
system, Rh2HAZnO accumulated on the cell surfaces after
3 hrs of treatment. Mito-Tracker analysis was performed
with or without treatment of Rh2HAZnO for 24 hrs to
detect the changes in mitochondria to predict apoptotic cell
death–mediated pathway mechanism Figure 2B. At 10 and
20 µg/mL Rh2HAZnO treated cell lines showed signiﬁ-
cant bright ﬂuorescence staining with damaged mitochon-
drial and intracellular debris with prominent stained
nucleus indicated that Rh2HAZnO targeting mitochondrial
mediated apoptosis by damaging the outer cellular mem-
brane in A549 cells. Whereas, in control cell lines, there
was no signiﬁcant damage in intracellular organelles
which indicated that no or less staining.
In Vitro Cell Cytotoxicity Of Rh2HAZnO
For evaluation of apoptosis induction and potential anti-
proliferative effect of this nanoparticle, three different
cancer cells were treated with Rh2, HAZnO and
Rh2HAZnO for 24 hrs, respectively (Figure 3A–C). A
signiﬁcant reduction in cell viability was observed at 10
µg/mL in all three cell lines for Rh2HAZnO, respectively
(Figure 3D). The reduced systemic toxicity of the drug-
conjugated nano-formulation can be attributed to the pre-
sence of ginsenoside Rh2 in the nanocomposites. Based on
the comparison of cell viability in the presence of Rh2,
HAZnO, and Rh2HAZnO in A549 (lung), HT29 (colon),
and MCF7 (breast) cancer cells, MCF-7 cell lines were the
most inhibited by Rh2HAZnO. We also observed cytotoxi-
city of HA, Rh2, HAZnO and Rh2HAZnO with normal
human keratinocytes (HaCaTs) (Figure 3E).
Intracellular ROS Evaluation In Three
Different Cancer Cell Lines
To analyze the free radical scavenging by the treatment of
Rh2HAZnO, DPPH assay was performed. It showed sig-
niﬁcant changes at 1.5mg/mL to compare with positive
control gallic acid. For intracellular ROS evaluation,
cells were treated with Rh2, HAZnO, and Rh2HAZnO
for 24 hrs. The increase of ROS was probed by
DCFH-DA (Figure 4A–C). Rh2HAZnO from the natural
source has been reported to exhibit cell death in various
cancer cells (A549, HT29, and MCF-7) through DNA
damage by the generation of ROS and activation of multi-
ple pro-apoptotic markers.20,21 The feature of ZnONPs is
their capability to generate ROS at their surface, which can
lead to cell death when the ROS levels exceed the anti-
oxidant capacity of the cell. Therefore, ZnONPs have
recently expanded prodigious interest in biomedical appli-
cations such as antibacterial and anticancer therapies. ROS
generated on the surface of the ZnONPs, and particle
dissolution and subsequent release of free Zn2+ ions that
lead to ROS production within cells.22 Thus, determination
of the antiproliferation effect of Rh2HAZnO was done
through evaluation of with measurement of ROS level.
Intracellular ROS production in cancer cell lines A549
Kim et al Dovepress
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(Figure 4A), HT29 (Figure 4B), and MCF7 (Figure 4C)
was highly related to Rh2HAZnO. Several studies have
reported the ability of various Rh2HAZnO synthesized
from natural sources to induce toxicity in cancer cells.
Figure 2 Total internal reﬂection scattering images (TIRS) and photoluminescence (PL) spectrum.
Notes: (A) Total internal reﬂection scattering images (TIRS) of Rh2HAZnO which was treated for lung cancer A549. Lung cancer cell; zinc oxide; cell+ Rh2HAZnO. (B)
Mito-Tracker and nucleus staining analysis after the treatment Rh2HAZnO nanoparticles.
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Likewise, the eco-friendly Rh2HAZnO could induce
higher toxicity to cancer cells. Previously, it has been
documented that the possible mechanisms of AgNP toxi-
city include induction of ROS, oxidative stress, DNA
damage, and apoptosis in various cell lines.21 Oxidative
stress is a known mechanism of nanomaterial-induced cell
death in various types of cell lines.23
Rh2HAZnO Caused Nuclear Damage To
Cancer Cells
A549, HT29, and MCF-7 cancer cells were monitored
after different concentrations of Rh2HAZnO treatment by
performing Hoechst-33258 staining. In untreated cells, the
cell wall remains intact, and the Hoechst dye remains
impermeable and thus caused reduced staining of cells.
Whereas, when the cells were treated with Rh2HAZnO,
the cell walls of cancer cells damaged due to the penetra-
tion of the dye into the cells and showed positive apoptotic
cells (Figure 5A1, B1, and C1). The results showed that
gradual increase in morphological alteration reached its
maximum when cells were treated with a high concentra-
tion of Rh2HAZnO. In addition, the cell size and number
were also signiﬁcantly reduced, which is evident that
Rh2HAZnO resulted in the detachment of cells and caused
alternation in morphology.
Rh2HAZnO Treatment Induced
Apoptosis Of Cancer Cells
Lung cancer (A549), colon cancer (HT29), and breast can-
cer (MCF-7) cells were treated with Rh2, HAZnO and
Rh2HAZnO to induce nuclear cell death by involving apop-
totic mechanism by upregulating the caspase-9/activation of
stress-responsive mitogen-activated protein kinases
(MAPKs) gene expression such as phosphorylation of
p38. The antiapoptotic member, BCL2, and the proapopto-
tic member, BAX, have been proven to be one of the most
critical players in the intrinsic apoptosis pathway.24,25 The
ratio of BAX/BCL2 is a key factor regulating apoptosis.26
The ratio BAX/BCL2 signiﬁcantly increased in both A549
and HT29 cancer cells (Figure 5A3 and B3), while the
BAX/BCL2 ratio did not show signiﬁcant differences in
MCF-7 cancer cells (Figure 5C3).
Caspases (cysteine-aspartic acid proteases) play a vital
role in the apoptosis process through activation of caspase
Figure 3 Cytotoxicity evaluation in cancer cells.
Notes: Toxicity evaluation of ginsenoside Rh2, hyaluronic acid zinc nanoparticles (HAZnO), and Rh2HAZnO was assessed by MTTassay after 24 h. (A) Lung cancer (A549).
(B) Colon cancer (HT29). (C) Breast cancer (MCF-7). (D) Comparison of cell viability in A549 (lung), HT29 (colon), and MCF7 (breast) cancer cells. (E) The cell viability of
normal human keratinocytes (HaCaTs) was examined using MTTassay. Each bar represents the mean ± SE of duplicate samples of three independent experiments. *P < 0.05,
**P < 0.01, and ***P < 0.001 compared to the non-treated control. The difference was observed using Student’s t-test.
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cascades including the initiation of caspase-9.27 A previous
study demonstrated that application of pseudo-G-Rh2
induced intrinsic-mediated apoptosis in A549 cells by acti-
vation of p53 and caspase-9.28 Expression change of p53
correlated with expression change of two downstream
BCL2 family proteins, BAX and BCL2. This observation
agrees with the transcriptional expression change of p53 in
those three cell lines.
The expressions of CASP7, CASP9, and p53 in A549
cell line were analyzed by performing qPCR (Figure 6).
The expressions of CASP9 and p53 genes tend to increase
in A549 cells that are gradually with Rh2 or HAZnO.
Moreover, cells treated with Rh2HAZnO nanoparticles
further upregulated both CASP9 and p53 transcripts
(Figure 6C and D). In contrast, the expression of p53
through Western blot analysis did not exhibit increased
p53 accumulation, but the cells undergo apoptosis through
activation of CASP9 rather than p53 itself (Figure 6D).
Expression of the MAPK gene and phosphorylation of the
p38 MAPK protein were found no signiﬁcant difference in
A549 cell lines except cleaved PARP (Asp 214) protein.
To determine the potential apoptotic mechanism of
Rh2HAZnO in HT29 colon cancer cells, the relative
gene expression and the protein expression were assessed.
Upon Rh2 treatment, p53 expression was steadily down-
regulated by up to 0.45-fold in the HT29 colon cancer cell
line. Interestingly, gene and protein expression tend to
increase when cells are treated with HAZnO, and the
highest expression pattern was recorded when cells were
treated with Rh2HAZnO (Figure 7A, E, and G). The
expression of p21 was gradually downregulated when
cells were treated with Rh2, HAZnO or Rh2HAZnO,
which clearly shows that HT29 cells undergo
p53-mediated apoptosis (Figure 7). Ginsenosides Rh2
and Rd inhibit the growth of HT29 cells through activation
of apoptosis processes.29 A previous study in HCT116
colon cancer cells demonstrated that Rh2 induced apopto-
sis through activation of p53.30
For the detection of apoptosis in MCF7 breast cancer
cells, relative gene expressions of p53 and the cleaved
CASP3, 7, 9 were evaluated through Western blot analysis
(Figure 8). Activation of CASP7 and CASP9 pathways has
Figure 4 Intracellular ROS evaluation in three cancer cell lines.
Notes: Cells were treated with Rh2 (ginsenoside Rh2), HAZnO (hyaluronic acid zinc oxide nanoparticles) and Rh2HAZnO for 24 hrs, and the increase of ROS was probed
by DCFH-DA. Scale bar = 10 μm. (A) Lung cancer (A549). (B) Colon cancer (HT29). (C) Breast cancer (MCF-7). Each bar represents the mean ± SE of duplicate samples of
three independent experiments. *P < 0.05, **P < 0.01, and ***P < 0.001 compared to the non-treated control. The difference was observed using student’s t-test.
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been identiﬁed to play an essential role in apoptosis,
especially during apoptotic chromatin condensation and
DNA fragmentation in various cell lines. Furthermore,
the anti-proliferative effect of Rh2HAZnO has been
found to be related to activation of p38 MAPK, CASP9
genes, p38 MAPK, and CASP9 proteins during treatment,
as a result of the morphological changes in the nuclei of
MCF7 cells along with the cytotoxic effect and induction
of oxidative stress. The expression of p53 through Western
blot analysis did not show increased p53 accumulation,
indicating that MCF7 cells undergo apoptosis through
activation of CASP7 and CASP9 rather than p53 itself
(Figure 8B, C, and E)
The proposed mechanism of inducing apoptosis is illu-
strated in Figure 9. The cytotoxicity effect of Rh2HAZnO is
postulated from triggering intracellular reactive oxygen spe-
cies (ROS), which was observed in three different cancer
cells (Figure 4). The photoluminescent effect of ZnO initiates
electron transmission from the valence band to the conduc-
tion band, thus creating an electron–hole pair. The hole can
induce a sequence of photochemical reactions to generate
ROS at the NP surface in an aqueous suspension.70 ROS
generation by ZnONPs upon irradiation with UV light has
been utilized for photo-triggered anticancer and antibacterial
activities via ROS-induced damage to cell membranes, mito-
chondria, proteins, and DNA.31 The tumor suppressor pro-
tein p53 is a redox-active transcription factor that organizes
cellular responses upon a range of stresses including intra-
cellular induction of ROS.32 The increase in intracellular
ROS is associated with the magnitude of p53 protein
expression,33 which was also shown in the lung cancer
A549 cells (Figure 6D) and the colon cancer HT29 cells
(Figure 7D) while the opposite trend was observed in the
breast cancer MCF-7 cells (Figure 8D).
Figure 5 Evaluation of apoptosis in three cancer cell lines.
Notes: Cells were treated with Rh2 (ginsenoside Rh2), HAZnO (hyaluronic acid zinc oxide nanoparticles) and Rh2HAZnO for 24 hrs. Hoechst stained positive apoptotic
cells are indicated with white arrows (A1, B1, and C1). Scale bar = 10 μm. Relative gene expression was evaluated by RT-PCR (A2–C2 and A3–C3), and band density was
analyzed with ImageJ software. (A1–A3) Lung cancer (A549). (B1–B3) Colon cancer (HT29). (C1–C3) Breast cancer (MCF-7). Each bar represents the mean ± SE of
duplicate samples of three independent experiments. *P < 0.05, **P < 0.01, and ***P < 0.001 compared to the non-treated control. ++P < 0.01, and +++P < 0.001 compared
HAZnO with Rh2HAZnO. The difference was observed using Student’s t-test.
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The increasing ratio BAX/Bcl-2 results in the formation
of apoptosome and activation of its effector, CASP9,34,35
which was indicated as the increased transcriptional expres-
sion of CASP9 in A549, HT29, and MCF-7 cancer cells
Figure 6 Potential apoptotic mechanism of Rh2HAZnO in A549 lung cancer cells.
Notes: Cells were treated with Rh2 (ginsenoside Rh2), HAZnO (hyaluronic acid zinc oxide nanoparticles) and Rh2HAZnO for 24 hrs (A). The relative analysis was analyzed
with ImageJ software (B–D). Protein expression was evaluated by Western blotting (E). Each bar represents the mean ± SE of duplicate samples of three independent
experiments. *P < 0.05, **P < 0.01, and ***P < 0.001 compared to the non-treated control. +++P < 0.001 compared HAZnO with Rh2HAZnO. The difference was observed
using Student’s t-test.
Figure 7 Potential apoptotic mechanism of Rh2HAZnO in HT29 colon cancer cells.
Notes: Cells were treated with Rh2 (ginsenoside Rh2), HAZnO (hyaluronic acid zinc oxide nanoparticles) and Rh2HAZnO for 24 hrs. Relative gene expression was
evaluated by RT-PCR (A), and band density analysis was done with ImageJ software (B–F). Protein expression was evaluated by Western blotting (G). Each bar represents
the mean ± SE of duplicate samples of three independent experiments. **P < 0.01, and ***P < 0.001 compared to the non-treated control. ++P < 0.01, and +++P < 0.001
compared HAZnO with Rh2HAZnO. The difference was observed using Student’s t-test.
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(Figures 6C, 7D, and 8C). The activation of CASP9 contrib-
uted to the activation of CASP7 in MCF-7 cells (Figure 8B).
Since CASP7 is one of the two effectors of mitochondrial
events of apoptosis,36,37 the series of expressional change of
apoptosis-related proteins indicated that the ROS stress
induced by Rh2HAZnO results in mitochondria-mediated
apoptosis. This postulation was also conﬁrmed with an
increase of cleaved PARP in the HT29 colon cancer cells.
Our data for the ﬁrst time showed that Rh2HAZnO
inhibits the proliferation of cancer cells by inducing apop-
totic-mediated cell death. This result suggests that
Rh2HAZnO might serve as a potential antitumor agent
against various cancer cells with further proper in vivo
experimental analysis.
Conclusion
In this study, we evaluate the potential of Rh2HAZnO to
induce apoptosis and DNA damage in lung cancer (A549),
colon cancer (HT29), and breast cancer (MCF7) cells,
respectively. It has been identiﬁed that, among different
caspase pathways, activation of the caspase-9 pathway is
required for apoptosis by Rh2HAZnO. Furthermore, the
effects of Rh2HAZnO on Caspase-9/p38 MAPK markers
were elucidated for anticancer activity.
Acknowledgments
This work was supported by a grant from the Basic
Science Research Program through the National
Research Foundation of Korea funded by the Ministry
of Education (2019R1A2C1010428) and NG-BioGreen
Figure 8 Potential apoptotic mechanism of Rh2HAZnO in MCF-7 breast cancer cells.
Notes: Cells were treated with Rh2 (ginsenoside Rh2), HAZnO (hyaluronic acid zinc oxide nanoparticles) and Rh2HAZnO for 24 hrs. Relative gene expression was
evaluated by RT-PCR (A), band density analysis was analyzed with ImageJ software (B–D). Protein expression was evaluated by Western blotting (E). Each bar represents the
mean ± SE of duplicate samples of three independent experiments. **P < 0.01, and ***P < 0.001 compared to the non-treated control. +++P < 0.001 compared HAZnO with
Rh2HAZnO. The difference was observed using Student’s t-test.
Figure 9 The proposed mechanism of the apoptotic effect of Rh2HAZnO on the
three different cancer cells: A549 (lung), HT29 (colon), and MCF7 (breast) cancer cells.
Kim et al Dovepress
submit your manuscript | www.dovepress.com
DovePress
International Journal of Nanomedicine 2019:148206
 
In
te
rn
at
io
na
l J
ou
rn
al
 o
f N
an
om
ed
ici
ne
 d
ow
nl
oa
de
d 
fro
m
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
11
4.
70
.7
.2
03
 o
n 
28
-O
ct
-2
01
9
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
21 program (SSAC, PJ0128132019), the Rural
Development Administration, Republic of Korea.
Author Contributions
YJK, HP and VC carried the experiment and wrote the
paper. DK and DCY analyzed the results based on the key
pathway for the conclusive description in the manuscript.
JM and YL carried out the production of HAZnRh2 nano-
particles. SL and SK carried out analysis of photolumines-
cent data and cell image. All authors contributed to data
analysis, drafting or revising the article, gave ﬁnal
approval of the version to be published, and agreed to be
accountable for all aspects of the work.
Disclosure
The authors report no conﬂicts of interest in this work.
References
1. World Health Organization. Global health observatory data reposi-
tory. 2011. Number of deaths (World) by cause. 2017.
2. Thun MJ, DeLancey JO, Center MM, Jemal A, Ward EM. The global
burden of cancer: priorities for prevention. Carcinogenesis. 2009;31
(1):100–110. doi:10.1093/carcin/bgp263
3. Coseri S. Natural products and their analogues as efﬁcient anticancer
drugs. Mini Rev Med Chem. 2009;9(5):560–571. doi:10.2174/
138955709788167592
4. Hartshorn CM, Bradbury MS, Lanza GM, et al. Nanotechnology
strategies to advance outcomes in clinical cancer care. ACS Nano.
2018;12(1):24–43. doi:10.1021/acsnano.7b05108
5. Wang R, Billone PS, Mullett WM. Nanomedicine in action: an over-
view of cancer nanomedicine on the market and in clinical trials. J
Nanomater. 2013;2013:1. doi:10.1155/2013/625739
6. You Q, Sun Q, Yu M, et al. BSA-bioinspired gadolinium hybrid-
functionalized hollow gold nanoshells for NIRF/PA/CT/MR quadmo-
dal diagnostic imaging-guided photothermal/photodynamic cancer
therapy. ACS Appl Mater Interfaces. 2017;9(46):40017–40030.
doi:10.1021/acsami.7b11926
7. Aditya A, Chattopadhyay S, Gupta N, et al. ZnO nanoparticles
modiﬁed with an amphipathic peptide show improved photoprotec-
tion in skin. ACS Appl Mater Interfaces. 2018;11(1):56–72.
doi:10.1021/acsami.8b08431
8. Sirelkhatim A, Mahmud S, Seeni A, et al. Review on zinc oxide
nanoparticles: antibacterial activity and toxicity mechanism. Nano
Micro Lett. 2015;7(3):219–242. doi:10.1007/s40820-015-0040-x
9. Kim DH. Gut microbiota-mediated pharmacokinetics of ginseng sapo-
nins. JGinseng Res. 2018;42(3):255–263. doi:10.1016/j.jgr.2017.04.011
10. Wong AS, Che C-M, Leung K-W. Recent advances in ginseng as
cancer therapeutics: a functional and mechanistic overview. Nat Prod
Rep. 2015;32(2):256–272. doi:10.1039/c4np00080c
11. Mathiyalagan R, Kim YJ, Wang C, et al. Protopanaxadiol aglycone
ginsenoside-polyethylene glycol conjugates: synthesis, physicochemical
characterizations, and in vitro studies. Artif Cells Nanomed Biotechnol.
2016;44(8):1803–1809. doi:10.3109/21691401.2015.1105236
12. Markus J, Mathiyalagan R, Kim YJ, et al. Synthesis of hyaluronic
acid and O-carboxymethyl chitosan-stabilized ZnO-ginsenoside Rh2
nanocomposites incorporated with aqueous leaf extract of dendropa-
nax morbifera léveille: in vitro studies as potential sunscreen agents.
New J Chem. 2019. doi:10.1039/C8NJ06044D
13. Zhou J, Xu NS, Wang ZL. Dissolving behavior and stability of ZnO
wires in bioﬂuids: a study on biodegradability and biocompatibility
of ZnO nanostructures. Adv Mater. 2006;18(18):2432–+.
doi:10.1002/adma.200600200
14. Xu F, Zhang P, Navrotsky A, et al. Hierarchically assembled porous
ZnO nanoparticles: synthesis, surface energy, and photocatalytic activ-
ity. Chem Mater. 2007;19(23):5680–5686. doi:10.1021/cm071190g
15. Wang C, Mathiyalagan R, Kim YJ, et al. Rapid green synthesis of
silver and gold nanoparticles using Dendropanax morbifera leaf
extract and their anticancer activities. Int J Nanomedicine.
2016;11:3691. doi:10.2147/IJN.S97181
16. Kim Y-J, Perumalsamy H, Markus J, et al. Development of
Lactobacillus kimchicus DCY51T-mediated gold nanoparticles for
delivery of ginsenoside compound K: in vitro photothermal effects
and apoptosis detection in cancer cells. Artif Cells Nanomed
Biotechnol. 2019;47(1):30–44. doi:10.1080/21691401.2018.1541900
17. Kovács D, Igaz N, Keskeny C, et al. Silver nanoparticles defeat p53-
positive and p53-negative osteosarcoma cells by triggering mitochon-
drial stress and apoptosis. Sci Rep Uk. 2016;6:27902. doi:10.1038/
srep27902
18. Dhillon AS, Hagan S, Rath O, KolchW.MAP kinase signalling pathways
in cancer. Oncogene. 2007;26(22):3279. doi:10.1038/sj.onc.1210421
19. Kim S, Shin DH, Kim J, et al. Energy transfer from an individual
silica nanoparticle to graphene quantum dots and resulting enhance-
ment of photodetector responsivity. Sci Rep Uk. 2016;6:27145.
20. Fang L, Cheng Q, Bai J, et al. An oncolytic adenovirus expressing
interleukin-24 enhances antitumor activities in combination with
paclitaxel in breast cancer cells. Mol Med Rep. 2013;8(5):1416–
1424. doi:10.3892/mmr.2013.1680
21. Sosa V, Moliné T, Somoza R, Paciucci R, Kondoh H, LLeonart ME.
Oxidative stress and cancer: an overview. Ageing Res Rev. 2013;12
(1):376–390. doi:10.1016/j.arr.2012.10.004
22. Wang B, Zhang YY, Mao ZW, Yu DH, Gao CY. Toxicity of ZnO
nanoparticles to macrophages due to cell uptake and intracellular
release of zinc ions. J Nanosci Nanotechno. 2014;14(8):5688–5696.
doi:10.1166/jnn.2014.8876
23. Chen T, Chen H, Wang Y, Zhang J. In vitro and in vivo antitumour
activities of puerarin 6 ″-O-xyloside on human lung carcinoma A549
cell line via the induction of the mitochondria-mediated apoptosis
pathway. Pharm Biol. 2016;54(9):1793–1799. doi:10.3109/138802
09.2015.1127980
24. Chen L, Gong M-W, Peng Z-F, et al. The marine fungal metabolite,
dicitrinone B, induces A375 cell apoptosis through the ROS-related
caspase pathway. Mar Drugs. 2014;12(4):1939–1958. doi:10.3390/
md12041939
25. Deng J. How to unleash mitochondrial apoptotic blockades to kill
cancers? Acta Pharm Sin B. 2017;7(1):18–26. doi:10.1016/j.apsb.
2016.08.005
26. Yuan Z, Jiang H, Zhu X, Liu X, Li J. Ginsenoside Rg3 promotes
cytotoxicity of Paclitaxel through inhibiting NF-κB signaling and
regulating Bax/Bcl-2 expression on triple-negative breast cancer.
Biomed Pharm. 2017;89:227–232. doi:10.1016/j.biopha.2017.02.038
27. Wang Y, Xu H, Lu Z, et al. Pseudo-Ginsenoside Rh2 induces A549
cells apoptosis via the Ras/Raf/ERK/p53 pathway. Exp Ther Med.
2018;15(6):4916–4924. doi:10.3892/etm.2018.6067
28. Yuan H-D, Quan H-Y, Zhang Y, Kim SH, Chung S-H. 20 (S)-
Ginsenoside Rg3-induced apoptosis in HT-29 colon cancer cells is
associated with AMPK signaling pathway. Mol Med Rep. 2010;3
(5):825–831. doi:10.3892/mmr.2010.328
29. Lee SY, Kim GT, Roh SH, et al. Proteome changes related to the anti-
cancer activity of HT29 cells by the treatment of ginsenoside Rd. Die
Pharmazie Int J Pharm Sci. 2009;64(4):242–247.
30. KingM,Murphy L. Role of cyclin inhibitor protein p21 in the inhibition
of HCT116 human colon cancer cell proliferation by American ginseng
(Panax quinquefolius) and its constituents. Phytomedicine. 2010;17(3–
4):261–268. doi:10.1016/j.phymed.2009.06.008
Dovepress Kim et al
International Journal of Nanomedicine 2019:14 submit your manuscript | www.dovepress.com
DovePress
8207
 
In
te
rn
at
io
na
l J
ou
rn
al
 o
f N
an
om
ed
ici
ne
 d
ow
nl
oa
de
d 
fro
m
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
11
4.
70
.7
.2
03
 o
n 
28
-O
ct
-2
01
9
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
31. Zhang HJ, Chen BA, Jiang H, Wang CL, Wang HP, Wang XM. A
strategy for ZnO nanorod mediated multi-mode cancer treatment.
Biomaterials. 2011;32(7):1906–1914. doi:10.1016/j.biomaterials.20
10.11.027
32. Smiles W, Camera D. The guardian of the genome p53 regulates
exercise-induced mitochondrial plasticity beyond organelle biogen-
esis. Acta Physiologica. 2018;222(3):e13004. doi:10.1111/apha.12
884
33. Macip S, Igarashi M, Berggren P, Yu J, Lee SW, Aaronson SA.
Inﬂuence of induced reactive oxygen species in p53-mediated cell
fate decisions. Mol Cell Biol. 2003;23(23):8576–8585. doi:10.1128/
mcb.23.23.8576-8585.2003
34. Guo -X-X, Guo Q, Li Y, Lee S, Wei X-N, Jin Y-H. Ginsenoside rh2
induces human hepatoma cell apoptosisvia bax/bak triggered cyto-
chrome C release and caspase-9/caspase-8 activation. Int J Mol Sci.
2012;13(12):15523–15535. doi:10.3390/ijms131215523
35. RenatusM, Stennicke HR, Scott FL, Liddington RC, Salvesen GS. Dimer
formation drives the activation of the cell death protease caspase 9. Proc
Natl Acad Sci. 2001;98(25):14250–14255. doi:10.1073/pnas.231465798
36. Wolan DW, Zorn JA, Gray DC, Wells JA. Small-molecule activators
of a proenzyme. Science. 2009;326(5954):853–858. doi:10.1126/
science.1177585
37. Riedl SJ, Salvesen GS. The apoptosome: signalling platform of cell
death. Nat Rev Mol Cell Biol. 2007;8(5):405. doi:10.1038/nrm2153
International Journal of Nanomedicine Dovepress
Publish your work in this journal
The International Journal of Nanomedicine is an international, peer-
reviewed journal focusing on the application of nanotechnology in
diagnostics, therapeutics, and drug delivery systems throughout the
biomedical ﬁeld. This journal is indexed on PubMed Central,
MedLine, CAS, SciSearch®, Current Contents®/Clinical Medicine,
Journal Citation Reports/Science Edition, EMBase, Scopus and the
Elsevier Bibliographic databases. The manuscript management system
is completely online and includes a very quick and fair peer-review
system, which is all easy to use. Visit http://www.dovepress.com/
testimonials.php to read real quotes from published authors.
Submit your manuscript here: https://www.dovepress.com/international-journal-of-nanomedicine-journal
Kim et al Dovepress
submit your manuscript | www.dovepress.com
DovePress
International Journal of Nanomedicine 2019:148208
 
In
te
rn
at
io
na
l J
ou
rn
al
 o
f N
an
om
ed
ici
ne
 d
ow
nl
oa
de
d 
fro
m
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
11
4.
70
.7
.2
03
 o
n 
28
-O
ct
-2
01
9
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
